NI201500072A - Inhibidores de bmi-1 de pirimidina inversa sustituida - Google Patents

Inhibidores de bmi-1 de pirimidina inversa sustituida

Info

Publication number
NI201500072A
NI201500072A NI201500072A NI201500072A NI201500072A NI 201500072 A NI201500072 A NI 201500072A NI 201500072 A NI201500072 A NI 201500072A NI 201500072 A NI201500072 A NI 201500072A NI 201500072 A NI201500072 A NI 201500072A
Authority
NI
Nicaragua
Prior art keywords
bmi
reverse
inhibitors
pyrimidine
inhibit
Prior art date
Application number
NI201500072A
Other languages
English (en)
Inventor
Lee Chang-Sun
Baiazitov Ramil
Cao Liangxian
w davis Thomas
Du Wu
Liu Ronggang
Moon Young-Choon
D Paget Steven
Ren Hongyu
Sydorenko Nadiya
Gerald Wilde Richard
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of NI201500072A publication Critical patent/NI201500072A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hematology (AREA)
  • Oncology (AREA)

Abstract

Compuestos inversos de pirimidina sustituidos con amina y formas de la misma que inhiben la función y reduce el nivel de la proteína del sitio de integración 1 (Bmi-1) del virus de la leucemia de Moloney específico de célula B para su uso para inhibir la función de Bmi-1 y reducir el nivel de Bmi-1 para el tratamiento de un cáncer mediado por Bmi-1 se describen en el presente documento.
NI201500072A 2012-11-21 2015-05-21 Inhibidores de bmi-1 de pirimidina inversa sustituida NI201500072A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261728907P 2012-11-21 2012-11-21

Publications (1)

Publication Number Publication Date
NI201500072A true NI201500072A (es) 2016-01-18

Family

ID=50776672

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201500072A NI201500072A (es) 2012-11-21 2015-05-21 Inhibidores de bmi-1 de pirimidina inversa sustituida

Country Status (32)

Country Link
US (3) US10428050B2 (es)
EP (1) EP2922828B1 (es)
JP (3) JP6412503B2 (es)
KR (4) KR102455889B1 (es)
CN (2) CN111423417B (es)
AR (1) AR093579A1 (es)
AU (1) AU2013348009C1 (es)
BR (1) BR112015011760B1 (es)
CA (1) CA2892045C (es)
CL (1) CL2015001377A1 (es)
CR (1) CR20150294A (es)
CU (1) CU24387B1 (es)
DK (1) DK2922828T3 (es)
EA (2) EA031405B1 (es)
EC (1) ECSP15019948A (es)
ES (1) ES2821529T3 (es)
HK (1) HK1215032A1 (es)
IL (2) IL238871B (es)
MA (1) MA38208B1 (es)
MX (2) MX2015006469A (es)
NI (1) NI201500072A (es)
NZ (2) NZ708909A (es)
PE (1) PE20151413A1 (es)
PH (1) PH12015501130A1 (es)
PL (1) PL2922828T3 (es)
PT (1) PT2922828T (es)
SA (1) SA517381847B1 (es)
SG (2) SG10201600149VA (es)
TW (1) TWI623531B (es)
UA (1) UA118094C2 (es)
WO (1) WO2014081906A2 (es)
ZA (1) ZA201503642B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201600149VA (en) 2012-11-21 2016-02-26 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CN105593215B (zh) * 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
EP3039015B1 (en) 2013-08-30 2019-10-30 PTC Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
WO2017027709A1 (en) 2015-08-11 2017-02-16 Cognoa, Inc. Methods and apparatus to determine developmental progress with artificial intelligence and user input
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
CN108602775B (zh) * 2016-01-14 2022-04-29 贝思以色列女会吏医学中心公司 肥大细胞调节剂及其用途
EP3580700A4 (en) * 2017-02-09 2020-11-18 Cognoa, Inc. PLATFORM AND SYSTEM FOR DIGITAL PERSONALIZED MEDICINE
WO2019028171A1 (en) 2017-08-01 2019-02-07 Ptc Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
BR112021002630A2 (pt) * 2018-08-17 2021-05-11 Ptc Therapeutics, Inc. método para tratar câncer pancreático
CN109988172B (zh) * 2019-01-10 2020-09-29 石家庄学院 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
EP3911418A1 (en) * 2019-01-15 2021-11-24 PTC Therapeutics, Inc. Method for treating an acute myeloid leukemia
EP3931196A4 (en) * 2019-02-28 2022-12-14 PTC Therapeutics, Inc. METHODS OF TREATMENT OF MULTIPLE MYELOMA
JP2022524424A (ja) 2019-03-11 2022-05-02 ピーティーシー セラピューティクス， インコーポレイテッド 向上したバイオアベイラビリティを有する化合物形態及びその製剤
KR102643554B1 (ko) 2019-03-22 2024-03-04 코그노아, 인크. 개인 맞춤식 디지털 치료 방법 및 디바이스
EA202192349A1 (ru) * 2019-03-27 2022-02-01 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Комбинации, пригодные в способе лечения саркомы
BR112021019508A2 (pt) * 2019-04-02 2022-02-01 Hinova Pharmaceuticals Inc Composto de amina aromática e uso do mesmo na preparação de reguladores e inibidores duplos de ar e brd4

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (es) * 1973-09-20 1977-11-30 Delalande Sa
CA2197298C (en) 1994-08-13 1999-10-19 Jong Wook Lee Novel pyrimidine derivatives and processes for the preparation thereof
IN188411B (es) 1997-03-27 2002-09-21 Yuhan Corp
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
JP2003523942A (ja) 1999-06-30 2003-08-12 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
ATE396978T1 (de) 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
ES2254238T3 (es) 1999-10-27 2006-06-16 Novartis Ag Compuestos de tiazol e imidazo(4,5-b)piridina y su uso farmaceutico.
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
CN100355751C (zh) 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途
JP4105948B2 (ja) 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
WO2002024681A2 (en) 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
US6716851B2 (en) 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
EP1351691A4 (en) * 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
DE60112330T2 (de) 2000-12-15 2006-04-13 Glaxo Group Ltd., Greenford Pyrazolopyridinderivate
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
ATE416175T1 (de) 2001-02-20 2008-12-15 Astrazeneca Ab 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen
EP1364212B1 (en) 2001-03-02 2011-02-02 GPC Biotech AG Three hybrid assay system
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
ES2271283T3 (es) 2001-07-03 2007-04-16 Vertex Pharmaceuticals Incorporated Isoxazolil-pirimidinas como inhibidores de las proteinas quinasas src y lck.
US7109204B2 (en) 2001-08-01 2006-09-19 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2003212634A1 (en) 2002-03-11 2003-09-22 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
WO2003099811A1 (en) 2002-05-23 2003-12-04 Cytopia Pty Ltd Kinase inhibitors
ATE447560T1 (de) 2002-06-28 2009-11-15 Nippon Shinyaku Co Ltd Amidderivat
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004007407A2 (en) * 2002-07-11 2004-01-22 Fluorous Technologies Incorporated Fluorous tagging and scavenging reactants and methods of synthesis and use thereof
US20040110821A1 (en) * 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
JP2006504755A (ja) 2002-10-15 2006-02-09 スミスクライン ビーチャム コーポレーション Ｇｓｋ−３阻害薬としてのピリダジン化合物
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
CN100465173C (zh) 2004-01-12 2009-03-04 西托匹亚研究有限公司 选择性激酶抑制剂
WO2005076854A2 (en) 2004-02-04 2005-08-25 Smithkline Beecham Corporation Pyrimidinone compounds useful as kinase inhibitors
EP2332940B1 (en) 2004-03-30 2012-10-31 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
EP1854793A4 (en) 2005-02-28 2011-01-26 Japan Tobacco Inc NEW AMINOPYRIDEIN COMPOUND WITH SYK-HEMDERING EFFECT
EP1858882A1 (en) 2005-03-10 2007-11-28 Bayer Pharmaceuticals Corporation Pyrimidine derivatives for treatment of hyperproliferative disorders
JP2009541268A (ja) 2006-06-22 2009-11-26 ビオヴィトルム・アクチボラゲット（プブリクト） Ｍｎｋキナーゼ阻害剤としてのピリジンおよびピラジン誘導体
CN101516873A (zh) * 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
AU2007304195A1 (en) 2006-10-03 2008-04-10 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
MX2009004019A (es) 2006-10-19 2009-06-19 Signal Pharm Llc Compuestos heteroarilo, composiciones de los mismos, y uso de los mismos como inhibidores de proteina cinasa.
JP2010514689A (ja) 2006-12-22 2010-05-06 ノバルティス アーゲー 癌、炎症およびウイルス感染症の処置のためのｃｄｋ阻害剤としてのヘテロアリール−ヘテロアリール化合物
PE20081636A1 (es) 2007-01-26 2009-01-10 Smithkline Beecham Corp Inhibidores de antranilamida para aurora quinasa
EP2121633A2 (en) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
UY31048A1 (es) 2007-04-25 2008-11-28 Astrazeneca Ab Nuevos compuestos de pirimidina y usos de los mismos
GB0714573D0 (en) 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
EP2203436A1 (en) 2007-09-17 2010-07-07 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
MY152948A (en) 2007-11-16 2014-12-15 Incyte Corp 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
ES2374480T3 (es) 2007-12-07 2012-02-17 Novartis Ag Derivados pirazol y uso de los mismos como inhibidores de quinasas dependientes de ciclina.
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
BRPI0910668A2 (pt) 2008-04-22 2019-09-24 Portola Pharmaceutiacals Inc inibidores de proteína quinases
WO2010002985A1 (en) * 2008-07-01 2010-01-07 Ptc Therapeutics, Inc. Bmi-1 protein expression modulators
ES2378513T3 (es) 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
CN102177154A (zh) * 2008-09-02 2011-09-07 神经研究公司 吡唑基-嘧啶衍生物及其作为钾通道调节剂的应用
WO2010061903A1 (ja) * 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
WO2010092962A1 (ja) 2009-02-12 2010-08-19 アステラス製薬株式会社 へテロ環誘導体
EP2411387B1 (en) 2009-03-27 2015-08-19 VetDC, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
CN102459265A (zh) 2009-05-27 2012-05-16 雅培制药有限公司 激酶活性的嘧啶抑制剂
WO2010144416A1 (en) 2009-06-08 2010-12-16 Gaeta Federico C A SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
ES2604667T3 (es) 2009-06-17 2017-03-08 Vertex Pharmaceuticals Incorporated Inhibidores de la replicación de virus de influenza
EP2451802A1 (en) 2009-07-07 2012-05-16 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
MX2012000711A (es) 2009-07-15 2012-03-16 Abbott Lab Inhibidores de pirrolopirazina de cinasas.
CA2767089A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
JP2011136925A (ja) * 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
JP5734313B2 (ja) 2010-01-12 2015-06-17 アーべー・シオンス チアゾールおよびオキサゾールキナーゼ阻害剤
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
RU2562111C2 (ru) * 2010-08-19 2015-09-10 Ф.Хоффманн-Ля Рош Аг Конверсия соматических клеток в индуцированные репрограмированные нейрональные стволовые клетки (ирнск)
BR112013005889A2 (pt) 2010-09-13 2020-08-25 Novartis Ag triazinaoxadiazóis, composição farmacêutica que os compreende e uso dos mesmos
WO2012050884A2 (en) * 2010-09-28 2012-04-19 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
CA2819373A1 (en) 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
EP2678332B1 (en) 2011-02-25 2016-05-18 Yuhan Corporation Diaminopyrimidine derivatives and processes for the preparation thereof
JP6116554B2 (ja) 2011-07-07 2017-04-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ がんの処置のための置換されたアザ複素環
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
SG10201600149VA (en) 2012-11-21 2016-02-26 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
IL265253A (en) 2019-05-30
IL238871B (en) 2019-03-31
NZ746607A (en) 2019-11-29
JP2016504290A (ja) 2016-02-12
KR20220143164A (ko) 2022-10-24
MX2015006469A (es) 2015-10-29
SG11201503982XA (en) 2015-06-29
EP2922828A2 (en) 2015-09-30
SG10201600149VA (en) 2016-02-26
PT2922828T (pt) 2020-10-12
ECSP15019948A (es) 2016-01-29
NZ708909A (en) 2019-11-29
US20150315182A1 (en) 2015-11-05
ZA201503642B (en) 2020-10-28
AU2013348009A1 (en) 2015-06-04
US11180483B2 (en) 2021-11-23
KR102356487B1 (ko) 2022-02-08
KR20210088740A (ko) 2021-07-14
IL238871A0 (en) 2015-07-30
JP6617186B2 (ja) 2019-12-11
CN111423417B (zh) 2022-11-15
BR112015011760A2 (pt) 2017-07-11
PE20151413A1 (es) 2015-10-23
EP2922828A4 (en) 2016-07-27
PH12015501130A1 (en) 2015-08-03
BR112015011760B1 (pt) 2022-12-06
AU2013348009C1 (en) 2019-08-08
MA38208B1 (fr) 2021-12-31
KR102455889B1 (ko) 2022-10-17
JP6918898B2 (ja) 2021-08-11
US20220064150A1 (en) 2022-03-03
CA2892045A1 (en) 2014-05-30
CU24387B1 (es) 2019-03-04
AU2013348009B2 (en) 2018-05-17
TWI623531B (zh) 2018-05-11
EP2922828B1 (en) 2020-07-08
WO2014081906A3 (en) 2014-07-17
AR093579A1 (es) 2015-06-10
EA201590992A1 (ru) 2015-11-30
WO2014081906A2 (en) 2014-05-30
UA118094C2 (uk) 2018-11-26
ES2821529T3 (es) 2021-04-26
HK1215032A1 (zh) 2016-08-12
US10428050B2 (en) 2019-10-01
KR20220016305A (ko) 2022-02-08
JP2019031509A (ja) 2019-02-28
CR20150294A (es) 2015-08-20
PL2922828T3 (pl) 2020-12-28
CN104918919A (zh) 2015-09-16
US20200024260A1 (en) 2020-01-23
CN111423417A (zh) 2020-07-17
CA2892045C (en) 2022-05-31
CU20150053A7 (es) 2015-11-27
DK2922828T3 (da) 2020-08-31
EA031405B1 (ru) 2018-12-28
EA201890142A1 (ru) 2018-06-29
MX2021009892A (es) 2021-09-14
CL2015001377A1 (es) 2016-02-19
SA517381847B1 (ar) 2021-07-17
KR20150086345A (ko) 2015-07-27
EA035349B1 (ru) 2020-05-29
TW201427972A (zh) 2014-07-16
KR102275676B1 (ko) 2021-07-12
JP2020055815A (ja) 2020-04-09
JP6412503B2 (ja) 2018-10-24

Similar Documents

Publication Publication Date Title
NI201500072A (es) Inhibidores de bmi-1 de pirimidina inversa sustituida
CL2020000060A1 (es) Compuestos antiproliferativos y métodos para utilizarlos.
UY37381A (es) Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CL2017003404A1 (es) Compuestos antibacterianos
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
MX370588B (es) Inhibidores de la bmi-1 de pirimidina sustituida.
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
CR20150462A (es) Inhibidores de erk y sus usos
CO2018006164A2 (es) Compuestos útiles como inhibidores de cinasa
CL2015002932A1 (es) Inhibidores de proteína quinasa
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
EA201692338A1 (ru) Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
EA201891626A1 (ru) Ингибиторы тирозинкиназы брутона
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CR20130306A (es) Compuestos y su uso
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
CL2015002113A1 (es) Compuestos de azetidinloxifenilpirrolidina
BR112017004000A2 (pt) formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida